Par's generic carisoprodol/aspirin
Firm received approval for the combination tablet formulation March 31. Carter-Wallace markets the muscle relaxant under the brand name Soma Compound, with estimated sales at $10 mil., Par said in an April 5 release. FDA had approved Par's ANDA June 7, 1988, but subsequently rescinded approval because of possible infringement on Carter-Wallace's formulation patent scheduled to expire 2002. Par has since certified that its generic does not infringe on the patent. Par is the second generic company to receive an ANDA approval for the combination product, following Bolar's approval in 1985.
You may also be interested in...
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
The US FDA wants to expand the availability of surgical apparel – including gowns, hoods and examination gloves – for health care professionals to use for the duration of the COVID-19 public health crisis. That means the agency will “not object” to the use of gowns and gloves providing low-to-minimal protection, as long as they do not create an undue risk to patients or users.